These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 29452492

  • 21. Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate.
    Joshi K, Pan X, Wang R, Yang E, Benson C.
    Curr Med Res Opin; 2016 Nov; 32(11):1873-1881. PubMed ID: 27479694
    [Abstract] [Full Text] [Related]

  • 22. Impact of Paliperidone Palmitate Versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans With Schizophrenia and Comorbid Substance Abuse.
    Lefebvre P, Muser E, Joshi K, DerSarkissian M, Bhak RH, Duh MS, Shiner B, Young-Xu Y.
    Clin Ther; 2017 Jul; 39(7):1380-1395.e4. PubMed ID: 28641996
    [Abstract] [Full Text] [Related]

  • 23. Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics.
    Pilon D, Alcusky M, Xiao Y, Thompson-Leduc P, Lafeuille MH, Lefebvre P, Benson C.
    J Med Econ; 2018 Feb; 21(2):135-143. PubMed ID: 28895766
    [Abstract] [Full Text] [Related]

  • 24. Economic Impact in Medicaid Beneficiaries with Schizophrenia and Cardiometabolic Comorbidities Treated with Once-Monthly Paliperidone Palmitate vs. Oral Atypical Antipsychotics.
    Lafeuille MH, Tandon N, Tiggelaar S, Kamstra R, Lefebvre P, Kim E, Yue Y, Joshi K.
    Drugs Real World Outcomes; 2018 Mar; 5(1):81-90. PubMed ID: 29363022
    [Abstract] [Full Text] [Related]

  • 25. Treatment patterns and hospitalizations following rejection, reversal, or payment of the initial once-monthly paliperidone palmitate long-acting injectable antipsychotic claim among patients with schizophrenia or schizoaffective disorder.
    Benson C, Patel C, Lee I, Shaikh NF, Wang Y, Zhao X, Near AM.
    J Manag Care Spec Pharm; 2024 Sep; 30(9):954-966. PubMed ID: 38831661
    [Abstract] [Full Text] [Related]

  • 26. A health economics study of long-acting injectable once-monthly paliperidone palmitate in schizophrenia: a one-year mirror-image study in China.
    Liu J, Wang Q, Su L, Yang L, Zou L, Bai L.
    BMC Psychiatry; 2022 Feb 08; 22(1):95. PubMed ID: 35135512
    [Abstract] [Full Text] [Related]

  • 27. Projecting the economic outcomes of switching patients with schizophrenia from oral atypical antipsychotics to once-monthly, once-every-3-months, and once-every-6-months paliperidone palmitate.
    Morrison L, Lin D, Benson C, Ghelerter I, Vermette-Laforme M, Lefebvre P, Pilon D.
    J Manag Care Spec Pharm; 2023 Feb 08; 29(2):161-171. PubMed ID: 36354209
    [Abstract] [Full Text] [Related]

  • 28. Impact of paliperidone palmitate versus oral atypical antipsychotics on healthcare outcomes in schizophrenia patients.
    Xiao Y, Muser E, Lafeuille MH, Pesa J, Fastenau J, Duh MS, Lefebvre P.
    J Comp Eff Res; 2015 Nov 08; 4(6):579-92. PubMed ID: 26168935
    [Abstract] [Full Text] [Related]

  • 29. Health Care Resource Utilization and Costs Associated with Transitioning to 3-month Paliperidone Palmitate Among US Veterans.
    DerSarkissian M, Lefebvre P, Joshi K, Brown B, Lafeuille MH, Bhak RH, Hellstern M, Bobbili P, Shiner B, El Khoury AC, Young-Xu Y.
    Clin Ther; 2018 Sep 08; 40(9):1496-1508. PubMed ID: 30145029
    [Abstract] [Full Text] [Related]

  • 30. Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup Analysis.
    Mathews M, Pei H, Savitz A, Nuamah I, Hough D, Alphs L, Gopal S.
    Clin Drug Investig; 2018 Aug 08; 38(8):695-702. PubMed ID: 29882073
    [Abstract] [Full Text] [Related]

  • 31. Comparison of long-acting and oral antipsychotic treatment effects in patients with schizophrenia, comorbid substance abuse, and a history of recent incarceration: An exploratory analysis of the PRIDE study.
    Lynn Starr H, Bermak J, Mao L, Rodriguez S, Alphs L.
    Schizophr Res; 2018 Apr 08; 194():39-46. PubMed ID: 28601497
    [Abstract] [Full Text] [Related]

  • 32. Persistence With and Adherence to Paliperidone Palmitate Once-Monthly Injection for Schizophrenia Treatment in China and Japan.
    Wang H, Zhang Y, Liu J, Chi R, Wu T, Zhang T, Zhang L, Jiang K, Qiu H, Dong W, Si T.
    J Clin Psychiatry; 2021 Dec 28; 83(1):. PubMed ID: 34963203
    [Abstract] [Full Text] [Related]

  • 33. Health Care Cost in Patients With Schizophrenia Treated With Brexpiprazole Versus Other Oral Atypical Antipsychotic Therapy.
    Yan T, Greene M, Chang E, Houle CR, Waters HC, Tarbox MH, Broder MS.
    Clin Ther; 2020 Jan 28; 42(1):77-93. PubMed ID: 31928831
    [Abstract] [Full Text] [Related]

  • 34. Continuity of care among patients newly initiated on second-generation oral or long-acting injectable antipsychotics during a schizophrenia-related inpatient stay.
    Patel C, Pilon D, Morrison L, Holiday C, Lafeuille MH, Lefebvre P, Benson C.
    Curr Med Res Opin; 2023 Aug 28; 39(8):1157-1166. PubMed ID: 37461233
    [Abstract] [Full Text] [Related]

  • 35. Healthcare Resource Utilization and Costs Among Patients With Schizophrenia Switching From Oral Risperidone/Paliperidone to Once-Monthly Paliperidone Palmitate: A Veterans Health Administration Claims Analysis.
    Patel C, Khoury AE, Huang A, Wang L, Bashyal R.
    Curr Ther Res Clin Exp; 2020 Aug 28; 92():100587. PubMed ID: 32714469
    [Abstract] [Full Text] [Related]

  • 36. Cost effectiveness of paliperidone palmitate versus oral antipsychotics in patients with schizophrenia and a history of criminal justice involvement.
    Muser E, Kozma CM, Benson CJ, Mao L, Starr HL, Alphs L, Fastenau J.
    J Med Econ; 2015 Aug 28; 18(8):637-45. PubMed ID: 25851616
    [Abstract] [Full Text] [Related]

  • 37. Adherence and economic impact of paliperidone palmitate versus oral atypical antipsychotics in a Medicare population.
    Joshi K, Muser E, Xu Y, Schwab P, Datar M, Suehs B.
    J Comp Eff Res; 2018 Aug 28; 7(8):723-735. PubMed ID: 29722547
    [Abstract] [Full Text] [Related]

  • 38. Real-world evidence of improved healthcare utilization in patients with schizophrenia or schizoaffective disorder after early treatment of paliperidone palmitate once-monthly treatment in Hong Kong.
    Choon JWY, Wu DBC, Chong HY, Lo WTL, Chong CSY, Chung WS, Chui EMC, Tomlinson B, Lee VWY, Lee SC, Lee KKC.
    J Med Econ; 2019 Mar 28; 22(3):273-279. PubMed ID: 30561238
    [Abstract] [Full Text] [Related]

  • 39. Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis.
    Lin D, Thompson-Leduc P, Ghelerter I, Nguyen H, Lafeuille MH, Benson C, Mavros P, Lefebvre P.
    CNS Drugs; 2021 May 28; 35(5):469-481. PubMed ID: 33909272
    [Abstract] [Full Text] [Related]

  • 40. An open-treatment six-week study of the clinical effectiveness of Paliperidone Palmitate in schizophrenia: data from acute units in Spain (SHADOW study).
    Parellada E, Bioque M, Serrano M, Herrera B, García Dorado M, SHADOW Study Group.
    Int J Psychiatry Clin Pract; 2018 Sep 28; 22(3):191-199. PubMed ID: 29161951
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.